Abstract
We present two Quality of Life (QOL) endpoints collected in conjunction with the recently completed Breast Cancer Prevention Trial (BCPT) performed by the National Surgical Adjuvant Breast and Bowel Project. The analyses of these endpoints (depression and hot flashes) indicate the importance of randomization and give some insight about the impact of missing data in a large randomized trial.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anelli, T.F., Anelli, A., Tran, K.N., Lebwohl, D.E. and Borgen, P.I. (1994). Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74, 74–77.
Bernhard, J., Cella, D.F., Coates, A.S., Fallowfield, L., Ganz, P., Moinpour, C.M., Mosconi, P., Osoba, D., Simes, J. and Hürny, C. (1998a). Missing quality of life data in cancer clinical trials: serious problems and challenges. Statistics in Medicine 17, 517–532.
Bernhard, J. and Gelber, R.D., eds. (1998b). Workshop on missing data in quality of life research in clinical trials: practical and methodological issues. Statistics in Medicine 17, 511–796.
Boyd, J.H., Weissman, M.M., Thompson, W.D. and Myers, J.K. (1982). Screening for depression in a community sample. Archives of General Psychiatry 39, 1195–1200.
Cathcart, C.K., Jones, S.E., Pumroy, C.S., Peters, G.N., Knox, S.M. and Cheek, J.H. (1993). Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment 27, 277–281.
Cella, D.F. and Bonomi, A.E. (1995). Measuring quality of life: 1995 update. Oncology 9 (11-suppl), 47–60.
Day, R., Ganz, P.A., Costantino, J.P., Cronin, W.M., Wickerham, D.L. and Fisher, B. (1999), Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-l study. Journal of Clinical Oncology 17, 2659–2669.
DeGruttola, V. and Tu, X.M. (1994). Modelling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics 50, 1003–1014.
Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., Vogel V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L. and Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l study. Journal of the National Cancer Institute 90, 1371–1388.
Gail, M.H., Costantino, J.P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K. and Vogel V. (1999). Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute 91, 1829–1846.
Ganz, P.A. (1994a). Long range effect of clinical trial interventions on quality of life. Cancer 74 (9-suppl), 2620–2624.
Ganz, P.A. (1994b). Quality of life measures in cancer chemotherapy: methodology and implications. Pharmacoeconomics 5, 376–388.
Ganz, P.A., Day, R., Ware, J.E., Redmond, C. and Fisher, B. (1995). Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. Journal of the National Cancer Institute 87, 1372–1382.
Ganz, P.A., Day, R. and Costantino, J. (1998). Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. Statistics in Medicine 17, 613–622.
Gregoire, A.J., Kumar, R., Everitt, B., Henderson, A.F. and Studd J.W. (1996). Transdermal oestrogen for treatment of severe postnatal depression. Lancet 347, 930–933.
Hahn, R. A. (1997). The nocebo phenomenon: concept, evidence, and implications for public health. Preventive Medicine 26, 607–611.
Halbreich, U. (1997). Role of estrogen in postmenopausal depression. Neurology 48 (5 Suppl7), S16–19.
Little, R.J.A. (1995). Modeling the drop-out mechanism in repeated measures studies. Journal of the American Statistical Association 90, 1112–1121.
Love, R.R., Cameron, L., Connell, B.L. and Leventhal H. (1991). Symptoms associated with tamoxifen treatment in postmenopausal women. Archives of Internal Medicine 151, 1842–1847.
Lyness, J.M., Noel, T.K., Cox, C., King, D.A., Conwell, Y., Caine, E.D. (1997). Screening for depression in elderly primary care patients: a comparison of the Center for Epidemiologic Studies-Depression Scale and the Geriatric Depression Scale. Archives of Internal Medicine 157, 449–454.
Moinpour, C.M., Savage, M.J., Troxel, A., Lovato, L.C., Eisenberger, M., Veith, R.W., Higgins, B., Skeel, R., Yee, M., Blumenstein, B.A., Crawford, E.D. and Meyskens, F.L. Jr. (1998). Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. Journal of the National Cancer Institute 90, 1537–1544.
Myers, J.K. and Weissman, M.M. (1980). Use of a self-report symptom scale to detect depression in a community sample. American Journal of Psychiatry 137, 1081–1084.
Radloff, L.S. (1977). The CES-D Scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1, 385–401.
Roberts, R.E. and Vernon, S.W. (1983). The Center for Epidemiologic Studies Depression Scale: its use in a community sample. American Journal of Psychiatry 140, 41–46.
Schluchter, M.D. (1992). Methods for the analysis of informatively censored longitudinal data. Statistics in Medicine 11, 1861–1870.
Shariff, S., Cumming, E., Lees, A., Handman, M. and Cumming, D.C. (1995). Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist: an expected or unexpected Effect? Annals of the New York Academy of Sciences 761, 365–368.
Sherbourne, C.D. (1992). Social functioning: sexual problems and measures. In: Stewart, A.L. and Ware, J.E. (eds.). Measuring Functioning and Well-Being: The Medical Outcomes Study Approach, Durham, North Carolina: Duke University Press.
Tannock, I.F., Osoba, D., Stockier, M.R., Ernst, D.S., Neville, A.J., Moore, M.J., Armitage, G.R., Wilson, J.J., Venner, P.M., Coppin, C.M. and Murphy, K.C. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology 14, 1756–1764.
Ten Have, T.R., Kunselman, A.R., Pulkstenis, E.P. and Landis, J.R. (1998). Mixed effects logistic regression models for longitudinal binary response data with informative drop-out. Biometrics 54, 367–383.
Ten Have, T.R., Miller, M.E., Reboussin, B.A. and James, M.K. (2000). Mixed effects logistic regression models for longitudinal ordinal functional response data with multiple-cause drop-out from the Longitudinal Study of Aging. Biometrics 56, 279–287.
Ware, J.E., Kosinski, M. and Keller, S.D. (1994). SF-36 Physical and Mental Summary Scales: A User’s Manual. Boston: The Health Institute, New England Medical Center.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Land, S. et al. (2002). Methodological Issues in the Analysis of Quality of Life Data in Clinical Trials: Illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. In: Mesbah, M., Cole, B.F., Lee, ML.T. (eds) Statistical Methods for Quality of Life Studies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3625-0_7
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3625-0_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5207-3
Online ISBN: 978-1-4757-3625-0
eBook Packages: Springer Book Archive